Table 2.
Results of treatment
| Total | sTIL+ | sTIL− | p | |
|---|---|---|---|---|
| Response to chemotherapy (case) | 0.030 | |||
| Treatment Sensitive (CR + PR) | 123 | 65 | 58 | |
| Treatment Resistant (SD + PD) | 36 | 12 | 24 | |
| Response to TRT (case)* | 0.045 | |||
| Treatment Sensitive (CR + PR) | 63 | 38 | 26 | |
| Treatment Resistant (SD + PD) | 18 | 6 | 12 | |
| mOS (moths) | 16 | 18 | 12 | 0.030 |
| 1, 2, 3-year OS rate | 59.8%, 28.6%, 19.8% | 72.2%, 37.5%, 25.1% | 48.0%, 19.9%, 5.1% | 0.030 |
| 1, 2, 3-year PFS rate | 31.5%, 13.1%, 6.2% | 37.2%, 21.0%, 14.0% | 25.9%, 4.2%, 4.2% | 0.013 |
| 1, 2, 3-year BMFS rate** | 75.0%, 47.2%, 47.2% | 75.1%, 66.0%, 66.0% | 75.5%, 11.4%, 11.4% | 0.023 |
*Patients administratived TRT and chemotherapy
**Patients with non-BM and non-PCI